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Edited by Lukas HuberAbstract This study describes the molecular signaling involved
in the diﬀerent cell death modes of triple-negative breast cancer
cells induced by hexadecylphosphocholine (HePC/miltefosine), a
clinically relevant anticancer alkylphosphocholine. We found
that the HePC treatment triggers cell-type-dependent apoptotic
and non-apoptotic cell death processes. Moreover, the expression
level of the apoptosis activator Fas, and Fas/Fas ligand signaling
capacity are not attributing factors for the preference toward
apoptosis. Using Fas siRNA and overexpression approaches we
establish that Fas is not a pro-apoptotic factor but a contributor
to cell protection in HePC-apoptosis-sensitive cells. The insight
in the multi-modal anticancer capability of HePC in triple-neg-
ative breast cancer cells may facilitate the targeted design of
therapeutic strategies against triple-negative breast cancers.
 2008 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Identiﬁcation of breast cancer subtypes has allowed targeted
therapies e.g., tamoxifen against luminal-like subtypes which
are predominantly oestrogen receptor (ER) positive and trast-
uzumab against Her2/neu-overexpressing subtype. This has
improved disease-free and overall survival in patients with
these speciﬁc markers. However, patients suﬀering triple-
negative (TN) breast cancers, which are predominantly ER-
negative, progesterone receptor (PR)-negative, and without
Her2/neu overexpression, do not beneﬁt from these targeted
therapies. These patients have a much worse prognosis, with
an increased risk of distant recurrence and rapid progression
to death [1]. Identifying therapeutic approaches to target this
aggressive type of breast cancer is thus a priority.
Hexadecylphosphocholine (HePC/miltefosine), an alkyl-
phosphocholine, has been approved as the topical treatment
for breast cancer skin metastases in several European countries
[2]. It has been shown an eﬃcient topical anti-tumoral treat-
ment in patients with cutaneous lymphoma [3], cutaneous
metastases of melanoma [4] and squamous cell carcinoma [5].
However, following clinical trials that include patients suﬀer-*Corresponding author. Fax: +33 492031245.
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doi:10.1016/j.febslet.2008.11.019ing squamous cell head and neck cancer [6], advanced soft tis-
sue sarcoma [7], and metastatic colorectal cancer [8], where it
provided limited beneﬁts, the development of oral HePC treat-
ment was suspended since the plasma level of HePC in these
patients could not achieve the expected range (at the time) of
in vitro anti-tumor activity (due to a dose-limiting gastrointes-
tinal toxicity). Despite the animal models and clinical studies
indicating selective anti-tumor activity of HePC as well as its
current usage as an eﬀective oral treatment against cutaneous
and visceral leishmaniasis [9], no trial has been conducted for
oral treatment of HePC in patients suﬀering TN breast can-
cers, where systemic HePC treatments may be beneﬁcial.
And while the anti-tumor eﬀects of HePC have long been dem-
onstrated, its mechanism remains unclear.
Fas (CD95/APO-1/TNFRSF6) is a classically known cell
death activator of the tumor-necrosis factor receptor (TNFR)
superfamily, which can also signal non-death activities, includ-
ing in cell protection, proliferation, and invasion, depending
on conditions [10]. The complex interactions between the
receptor and the plasma membrane are among essential deter-
minants of its cell death and non-death signaling [11,12].
The reported pro-apoptotic role of Fas in leukemic cells
treated with edelfosine (a representative of another anti-tumor
lipid class) [13] has led to a frequent extrapolation that Fas
also promotes apoptosis in HePC-treated cells, even though
the eﬀects and selectivity of alkylphosphocholines (e.g. miltefo-
sine/HePC and perifosine) and alkyl-lysophospholipids (e.g.
edelfosine and ilmofosine) have been diﬀerentiated earlier
[14]. To date, no proof of the requirement or pro-apoptotic
role of Fas in HePC-induced cancer cell death has been
reported.
This report describes the molecular mechanisms of cell-type-
dependent apoptotic and non-apoptotic cell death processes
triggered by HePC treatment of TN breast cancer cells, which
involves Akt and p38 signaling and Fas-mediated non-death
function.2. Materials and methods
2.1. Antibodies and reagents
HePC was obtained from Calbiochem. Antibodies against human
Fas (C20) and b-actin were from Santa Cruz; anti-Fas (CH11) from
Upstate, anti-caspase-8 and anti-caspase-9 (5B4) from MBL;
anti-phospho- and total p38 MAPK, and Akt from Cell Signaling
Technology; anti-ezrin from Zymed. Horseradish peroxidase conju-
gated anti-rabbit and anti-mouse antibodies and anti-mouse-IgM-
FITC were from Jackson ImmunoResearch. The anti-Flag (M2) from
Sigma was used for FasL crosslinking. The recombinant human FasLblished by Elsevier B.V. All rights reserved.
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and Fas siRNA were obtained from Eurogentec (SIMA, 5 0-CCCU-
ACAUCCCGAUCGAUG-3 0; Fas siRNA, 5 0-GAAGCGUAUGAC-
ACAUUGAUU-3 0).
2.2. Cell culture
The MCF-7, MDA-MB-231, and MDA-MB-435 cells were kindly
provided by Dr. Jacques Pouyssegur (Institute of Developmental
Biology and Cancer Research, CNRS UMR6543, France). CAL51
cells were obtained from the Centre Antoine Lacassagne (Nice,
France). The MCF-7 cells were derived from the pleural eﬀusion of
a white female with metastatic breast cancer [15]. They express ER
and PR, do not overexpress Her2/Neu, and exhibit luminal epithe-
lial-like phenotype [16]. The MDA-MB-231 breast cancer cells were
obtained from a pleural eﬀusion of a 51-year-old white female [17].
They are ER and PR negative and do not overexpress Her2/Neu
[17–19] (TN). The MDA-MB-435 cells are derived from M14 mela-
noma cells [20]. Both MDA-MB-231 and MDA-MB-435 exhibit
post-epithelial–mesenchymal transition (post-EMT) phenotype with a
high expression of vimentin and the loss of the expression of cytoker-
atins [21] and are highly invasive [22]. The CAL51 cells were estab-
lished from the metastatic pleural eﬀusion of a 45-year-old female
with progressive breast adenocarcinoma [23]. They exhibit normal
karyotype [23] and are TN cells [21,24] that exhibit the post-EMT phe-
notype with an expression of vimentin that is lower than in MDA-MB-
231 cells and the loss of expression of cytokeratins [21]. The cells were
maintained at sub-conﬂuence in Dulbeccos modiﬁed Eagles medium
(DMEM) with 10% fetal calf serum (FCS) at 37 C, 5% CO2. To per-
form transient transfection, 2 · 105 cells were plated in six-well plates
in DMEM + 10% FCS 24 h before transfection by calcium phosphate
precipitation with control pCR3 vector, human Fas construct, control
(SIMA) siRNA, or human Fas siRNA.
2.3. Cell death assays
To perform cell death assays, 4 · 105 cells were plated in six-well
plates in DMEM + 10% FCS 24 h before the experiments. Cells were
then incubated with or without the indicated amount of HePC or
Flag-tagged rhFasL plus 1 lg/ml anti-Flag Ab (M2), in DMEM
supplemented with 10% FCS at 37 C, 5% CO2 for an indicated time.
Total cell death was performed by staining cells with 5 lg/ml propidi-
um iodide (PI) before analyzing with a ﬂow cytometer (FACSCalibur;
Becton Dickinson) to assess the membrane integrity. Apoptotic cell
death assay was done by ﬁxing the cells after treatment with 70%
ethanol (20 C), washed in 38 mM sodium citrate (pH 7.4), then
stained with PI with RNase A, and analyzed by ﬂow cytometry
(FACS). The proportion of apoptotic cells represented by the sub-
G1 peak was determined [25] and represented as percent of cell death.
Data are presented as mean ± S.D. with n = 3. Student t-test was used
to test the statistical diﬀerence between means (*P > 0.05).
2.4. Preparation of detergent-resistant membrane microdomains (DRM)
Cells were plated in 14-cm dish 24 h before incubation with or with-
out 40 lMHePC for 1 h. Cells were scraped and washed with PBS and
solubilized in buﬀer A (25 mM HEPES, 150 mM NaCl, 1 mM EGTA,
protease inhibitors cocktail) containing 1% Brij 98 (Aldrich) for 1 h on
ice followed by addition of 2 ml of 2 M sucrose in buﬀer A before being
subjected to a step sucrose gradient ultracentrifugation as previously
described [11]. One-milliliter fractions were harvested from the top, ex-
cept for the bottom fraction (no. 9) which contained 3 ml. To an equal
volume of each fraction, Laemli buﬀer was added and the fractions
were heated at 95 C. Equal volume of each fraction was subjected
to SDS–PAGE and subsequent immunoblotting.3. Results and discussion
Despite urgent needs for eﬀective treatments, previous re-
ports on HePC-induced cell death have not included cells with
TN breast cancer characteristics. Thus we ﬁrst compared the
sensitivity toward HePC of two TN breast carcinoma cell lines,
CAL51 and MDA-MB-231, with that of the luminal model
breast cancer cells, MCF-7 [21], and the highly metastatic cells,MDA-MB-435, previously described as breast cancer cells but
recently shown originated from melanoma [20]. Unlike MCF-7
cells, the TN cells CAL51 and MDA-MB-231 as well as the
MDA-MB-435 cells were clearly sensitive to HePC treatment
(Fig. 1a, left).
The high sensitivity of TN breast cancer cells towards HePC
was previously claimed in studies where MaTu, MT-1, and
MT-3 cells were used [26–28]. However, it has been identiﬁed
that the MaTu and MT-1 cell lines are HeLa, a cervical adeno-
carcinoma cell line [29] and the MT-3 cell line is LS-174T, a co-
lon cell line [30]. Therefore, knowledge regarding the beneﬁt
from HePC treatment on TN breast cancers is very scarce.
Our ﬁndings indicate the possibility that the anti-tumor activ-
ity of HePC may indeed be more beneﬁcial for treatment of
TN breast cancers than of the luminal-type breast cancers.
Previous gene expression studies have shown that CAL51
and MDA-MB-231 exhibit the characteristics of breast cancer
having undergone an epithelial–mesenchymal transition (post-
EMT), as indicated by their expression of vimentin and the
loss of cytokeratin expression; and this gene proﬁle is shared
by the MDA-MB-435 cells but not the MCF-7 cells [21]. The
anticancer activity of HePC on breast cancer and melanoma
cells exhibiting the characteristics of EMT transition, which
is profoundly connected to metastasis and cancer progression,
warrants further investigation regarding the control of distant
metastases by this drug.
Although CAL51 and MDA-MB-231 cells were killed com-
parably by HePC (Fig. 1a, left), they underwent diﬀerent cell
death modes. This is based on the observation that while the
total cell death in HePC-treated CAL51 cells was attributed
entirely to classical apoptosis (according to the sub-G1 popu-
lation analysis representing cells with DNA fragmentation)
this clearly was not the case for the MDA-MB-231 cells
(Fig. 1a, right). Additionally, while the treated CAL51 cells
possessed the membrane blebbing morphology, characteristic
of apoptosis, the treated MDA-MB-231 cells acquired round
morphology (Fig. 1b). The lack of sub-G1 population and
the round morphology were also observed in MDA-MB-435
cells while no changes were observed in MCF-7 cells, conﬁrm-
ing their HePC resistance.
Accordingly, we observed the HePC-induced cleavage of
caspase-8 and caspase-9 and PARP (a caspase-3 substrate) in
CAL51 but not MDA-MB-231 and MDA-MB-435 cells
(Fig. 1c). The selective HePC-induced caspase-dependent
apoptosis in CAL51 cells was conﬁrmed by the observation
that the treatment with the pan-caspase inhibitor, zVAD,
attenuated the HePC-induced cell death in CAL51 cells but
not in the MDA-MB-231 and MDA-MB-435 cells (Fig. 1d).
Duijsings and colleagues have previously shown that in ca-
nine mammary tumor cell line (CMT-U335), HePC treatments
at 10 lM induced a rapid cell death with some characteristics
of apoptosis such as the externalization of phosphatidylserine
before the loss of plasma membrane integrity and nuclear con-
densation [31]. However, the reported cell death also exhibited
several features of primary necrosis, such as mitochondrial
swelling, dilated rough endoplasmic reticulum, and the lack
of membrane blebbing and DNA fragmentation. Also, cell
rounding and detachment were observed concomitantly with
the rapid cell death, which the authors suggested to have oc-
curred independently of caspase activity as these events could
not be inhibited by the treatment with zVAD (their unpub-
lished observations). These ﬁndings resemble what we ob-
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Fig. 1. Cell-type-dependent HePC-induced cell death. Cells were left untreated or treated with indicated amount of HePC then harvested and
subjected to (a) total cell death assay by membrane integrity assessment with PI staining (left) or apoptotic cell death assay by measuring the sub-G1
population which represent apoptotic cells (right). Results presented are after subtracting background cell death of untreated cells. (b) Cells were
visualized by light microscopy after 40 lMHePC treatment (or leaving untreated as control) for 18 h (or 9 h for MDA-MB-435 cells due to the more
rapid cell death, see (a)). (c) Cells were left untreated or treated with 40 lMHePC for indicated time then washed with PBS before collected in Laemli
buﬀer and subjected to SDS–PAGE and immunoblotting with indicated antibodies [11]. (d) Cells were pretreated for 30 min with 30 lM zVAD or
DMSO (control vehicle) before incubation with or without 40 lMHePC for 18 h (CAL51 and MDA-MB-231 cells) or 9 h (MDA-MB-435 cells) and
then subjected to total cell death assay as in (a). Statistical signiﬁcance is indicated (*) for the diﬀerence in % cell death between the indicate cell line
and the luminal-type MCF-7 cells.
4178 K. Chakrabandhu et al. / FEBS Letters 582 (2008) 4176–4184
K. Chakrabandhu et al. / FEBS Letters 582 (2008) 4176–4184 4179served for the MDA-MB-231 and MDA-MB-435 cells upon
HePC treatment, albeit with a more rapid kinetics.
The CMT-U335 cells, have been described by Hellmen and
coworkers as ER-negative and PR-positive and can form mes-
enchymal tumors in nude mice [32]. They also strongly express
vimentin, an intermediate ﬁlament protein associated with
high invasiveness. Notably, vimentin has also been shown
highly overexpressed in MDA-MB-231 and MDA-MB-435
cells, which exhibited similar HePC-induced cell death behav-
iors as the CMT-U335 cells, but less expressed in CAL51 cells
[21]. Thus it is possible that diﬀerent HePC-induced cell death
modes may correlate with the degree of cancer progression and
further investigations is called for.
Since HePC could reduce S473-phosphorylated (p-S473) Akt
protein level in epidermoid carcinoma cells [33], we investi-
gated whether this was the case in our cell systems. The
HePC-treated CAL51 cells exhibited a time-dependentAkt
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Fig. 2. Eﬀects of HePC treatment on Akt and p38 MAPK pathways. (a) Ce
immunoblot with indicated antibodies. (b and c) Intensity of bands from (a)
rsb.info.nih.gov/ij/). For each antibody used (phospho or total), bands were ﬁ
phospho/total protein ratios were calculated by dividing the normalized pho
initial baseline level (untreated) ratio equals 1 (dashed line).reduction of p-S473 Akt level, concomitantly with the reduced
total Akt protein expression. In MDA-MB-231 and MDA-
MB-435 cells, on the other hand, the reduction of p-S473
Akt was clearly observed at 7 h of the treatment without the
reduction of Akt expression (Fig. 2a). Comparing ratio of p-
S473 versus total Akt protein with regard to the untreated con-
dition, HePC treatment in MDA-MB-231 cells led to a drastic
increase in p-S473 Akt proportion at early treatment point be-
fore a progressive decline, reaching 50% of original phosphor-
ylation at 7 h (Fig. 2b). The dephosphorylation of Akt in
MDA-MB-231 cells at later treatment time resembled that ob-
served in MDA-MB-435 cells. However, the HePC treatment
did not result in the early hyperphosphorylation but a progres-
sive dephosphorylation in MDA-MB-435 cells. The HePC
treatment in CAL51 cells led only to a slight reduction of
Akt phosphorylation pool at 1 h of the treatment, which was
reestablished to the original proportion from 3 h on. It is thusontrol 1h 3h 7h
MDA-MB-435MDA-MB-231
control 1h 3h 7h
3 4 5 6 7 8
Time (h)
CAL51
MDA-MB-231
MDA-MB-435
3 4 5 6 7 8
Time (h)
CAL51
MDA-MB-231
MDA-MB-435
lls were treated and processed as described in Fig. 1c and subjected to
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rst normalized with the band from the untreated condition. The plotted
spho Akt (or p38) by normalized total Akt (or p38), and thus with the
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apoptotic death (MDA-MB-231 and MDA-MB-435), HePC
interferes with the phosphorylation status of Akt but not its
expression, suggesting its actions in the pathways regulating
the activity of Akt; whereas in cells undergoing HePC-induced
apoptosis (CAL51), HePC interferes with the expression of
Akt rather than its phosphorylation status, suggesting HePCs
roles in the pathways involving the stability rather than thecontrol
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rhFasL (or untreated) as in (b) then visualized by light microscopy.enzymatic activity of Akt. It is possible that the inhibition of
Akt survival pathway is an active process leading to HePC-
induced non-apoptotic death while Akt downregulation may
be a passive process, secondary to the activation of caspase-
dependent apoptotic machinery in HePC-induced apoptosis.
Further studies are required to investigate this hypothesis.
p38 MAPK has a broad physiological functions depending
on the cellular context and stimuli and has emerged as andcontrol
Anti-Fas Abas Ab
M1
Sub-G1
Control
+FasLontrol
xpression Fas surface expression
MDA-MB-435-231
tent DNA content
MDA-MB-435231
MB-231 MDA-MB-435
apoptosis
optosis do not deﬁne HePC-induced non-apoptosis/apoptosis. (a) Cells
d by FITC-conjugated anti-mouse IgM and analyzed by FACS for Fas
population of cells untreated (solid peak) or treated with 100 ng/ml of
cessed as described in Fig. 1a. (c) Cells were treated with crosslinked
K. Chakrabandhu et al. / FEBS Letters 582 (2008) 4176–4184 4181important regulator of cancer progression [34]. We observed
that HePC treatment of CAL51 cells resulted in the progres-
sive increase in p38 MAPK phosphorylation, despite a de-
crease in the protein level of p38 at the later treatment time
(Fig. 2a). The increased p38 phosphorylation in CAL51 cells
rather resembled that of MDA-MB-435 cells; however, the
p38 protein level did not decrease in the latter. In MDA-
MB-231 cells, the level of phosphorylated p38 protein exhib-
ited a similar dynamic to that of their p-S473 Akt level, namely
an increased phosphorylation at early time point followed by
the dephosphorylation at later time point, without the decrease
in total p38 level. Considering phospho versus total p38 ratios
with regard to the untreated condition, the treated MDA-MB-
231 cells exhibited p38 phosphorylation kinetics which resem-
bled that of p-S473 Akt, with a peaked p38 phosphorylation at
1 h after treatment followed by a progressive decline (Fig. 2b
and c). However, unlike the Akt phosphorylation, the p3811 2 3 4 5 6 7 8 9
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treated cells throughout the time observed. The HePC-treated
CAL51 cells, on the contrary, exhibited a strikingly similar p38
phosphorylation proﬁle to that of HePC-treated MDA-MB-
435 cells, namely a later onset of p38 hyperphosphorylation
at 3 h which continued to reach nearly 200% of the initial
phosphorylation level at 7 h of treatment.
Unlike with the Akt pathway, the fact that HePC potenti-
ated the activation p38 MAPK in all HePC-sensitive cells
tested, albeit with varying kinetics, with CAL51 and MDA-
MB-435 cells exhibiting strikingly similar p38 phosphorylation
proﬁles, suggests that the activation of this pathway may be
common in both apoptotic and non-apoptotic cell death in-
duced by HePC.
Having established that HePC triggered cell type-dependent
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for apoptosis induced by edelfosine, an alkyl-lysophospholipid
structurally related to HePC [13]. We found that neither the
Fas surface expression level nor the sensitivity to Fas/FasL-in-
duced apoptosis correlated with the HePC-induced apoptosis,
since the highest Fas surface expression was observed in the
MDA-MB-435 cells, followed by CAL51 and MDA-MB-231,
respectively (Fig. 3a); and all these cells were resistant to the
FasL-triggered apoptosis as shown by the lack of sub-G1
(Fig. 3b), cell death morphology (Fig. 3c), and PI staining
(membrane integrity, not shown) following FasL treatment.
Thus Fas surface expression level and the membrane-origi-
nated Fas/FasL apoptotic signaling capacity are not selecting
factors for HePC-induced apoptosis.
While Fas may not be a selective factor for HePC-induced
apoptosis, its pro-apoptotic role in edelfosine-treated cells
[13] led us to investigate whether this was the case in HePC-
treated CAL51 cells. The HePC treatment resulted in a weak
redistribution of Fas into the low-density, detergent-resistant
membrane microdomains (DRM, Fig. 4a), in line with the pos-
sible pro-apoptotic role of Fas in HePC-induced cell death, gi-
ven that Fas aggregation in microdomains has been suggested
essential for edelfosine-induced apoptosis [13]. This led us to
investigate whether Fas indeed promoted the HePC-induced
cell death. We observed that suppressing Fas expression with
siRNA did not reduce HePC-induced cell death but, instead,
promoted it (Fig. 4b). Correspondingly, overexpression of
Fas in CAL51 cells did not promote HePC-induced cell death
but rather attenuated it (Fig. 4c). This reduction in cell death
might be due to the attenuation of p38 MAPK pathway since
Fas overexpression also resulted in a decrease in phosphory-
lated p38 protein level whereas p-S473 Akt level remained un-
changed (Fig. 4d).
Altogether, these results suggest that the partition of Fas
into microdomains upon HePC treatment is not indicative of
the pro-apoptotic ability of Fas in HePC-treated triple-nega-
tive CAL51 cells and Fas rather contributes to the cell protec-
tion against HePC-induced apoptosis, possibly through
attenuation of p38 MAPK pathway.
Although the HePC-induced apoptosis in CAL51 cells was
not triggered by the apoptotic signaling of Fas, the caspase
activities played signiﬁcant roles in this process, in which the
activation of p38 MAPK was a major feature. Therefore, we
further investigated the relationship between the caspase activ-
ities and the activation of p38 MAPK. We observed that incu-
bating the cells with zVAD led to a signiﬁcant attenuation of3h 5h 7h 3h 5h 7h 3hTime (h)
HePC - +
Pretreatment Vehicle
Fig. 5. Caspases act upstream of p38 MAPK activation in HePC-induced ap
DMSO (vehicle) before incubation with or without 40 lM HePC for an indic
buﬀer and subjected to SDS–PAGE and immunoblotting with indicated antthe p38 MAPK phosphorylation and a stabilization of the to-
tal p38 MAPK expression upon the subsequent HePC treat-
ment; a complete reversion of the events in the control cells
treated with HePC alone, where the p38 MAPK overphosph-
orylation occurred concomitantly with the reduction of the to-
tal p38 MAPK level (Fig. 5).
The cross-talk between the p38 MAPK and caspase path-
ways has been reported. For example, the p38 MAPK associ-
ates to caspase-8 and caspase-3 during apoptosis in human
neurophil, where the activity of the MAPK correlates with
the phosphorylation of these caspases in primary cells; and
the immunoprecipitated active p38 MAPK can phosphorylate
and inhibit the activity of the active p20 subunits of caspase-8
and caspase-3 [35]. In this case, the p38 MAPK signals sur-
vival. On the other hand MEKK1, an upstream kinase that
can activate p38 MAPK, can be cleaved and activated by cas-
pase-3 and [36] and the MEKK1-mediated phosphorylation of
the p38 MAPK is an event downstream of the Bax-caspase-3
pathway in the apoptosis that is triggered by high D-glucose
in human endothelial cells [37]; and in this case, p38 MAPK
plays a pro-apoptotic role. Our data suggest that in the tri-
ple-negative CAL51 cell model, caspase pathway operates up-
stream of p38 MAPK pathway. One possible scenario could be
that caspase-3 cleaves and activates the MEKK1 which can, in
turn, activate p38 MAPK. More data are required to under-
stand the cross-talk between caspases and MAPK pathways
in HePC-induced cell death.
Currently, there are no eﬀective treatments against TN
breast cancers. We demonstrate here the sensitivity of TN
breast cancer cells to HePC, a drug that has already been in
the market in several countries for several years as topical
agent for cutaneous breast cancer metastatic treatment and
as oral agent for cutaneous and visceral leishmaniasis [9].
Notably, the dose that elicited the cell death of TN breast can-
cer cells presented in this study (40 lM) was well below the
maximum serum concentration attained during the oral HePC
treatment of leishmaniasis (172 lM) [38]. This aspect empha-
sizes the potential tolerability and beneﬁts of HePC in TN
breast cancer treatment. In addition, we reveal that HePC ex-
erts diﬀerent modes of action leading to diﬀerent cell death
processes, i.e. apoptosis or non-apoptosis, depending on TN
breast cancer cell types. These processes involve the activation
of p38 MAPK pathway and diﬀerential down regulation of
Akt signaling. We also demonstrate that Fas, a quintessential
death activator, is not the determining or promoting factor of
HePC-induced apoptosis. Instead, it is a protective contributorp38 MAPK
Ezrin
Phospho-T180/Y182 
p38 MAPK 
5h 7h 3h 5h 7h
- +
zVAD
optosis. CAL51 cells were pretreated for 30 min with 30 lM zVAD or
ated time. Cells were then washed with PBS before collected in Laemli
ibodies.
K. Chakrabandhu et al. / FEBS Letters 582 (2008) 4176–4184 4183in HePC-sensitive TN breast cancer cells, possibly through the
control of p38 MAPK activity, which also involves the cross-
talk with the HePC-induce caspase pathways. Our study pre-
sents the evidence of the cell-dependent multi-functions of
the commonly-presumed pro-apoptotic death receptor and
the regulation of MAPK-caspase cross-talk, which should be
taken into consideration in the study of breast cancer cell
death. The delineation of these intertwining pathways could re-
sult in therapeutic strategies with improved eﬃcacy.
Our study presents the potential of HePC, and possibly
other drugs in its class, in the treatment against TN breast can-
cers and brings more insight toward molecular players in-
volved. This may facilitate the design of targeted treatments
against this aggressive breast cancer subtype, which is consid-
ered one of the biggest priorities in the breast cancer research.Conﬂict of interest statement
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